Hudson Portfolio Management LLC Purchases Shares of 1,365 United Therapeutics Corporation $UTHR

Hudson Portfolio Management LLC purchased a new position in shares of United Therapeutics Corporation (NASDAQ:UTHR) in the 2nd quarter, HoldingsChannel.com reports. The institutional investor purchased 1,365 shares of the biotechnology company’s stock, valued at approximately $740,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of UTHR. BlackRock Inc. bought a new position in shares of United Therapeutics during the 2nd quarter valued at about $2,868,735,000. Wellington Management Group LLP lifted its position in United Therapeutics by 74.5% in the 4th quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock worth $1,189,617,000 after buying an additional 1,042,711 shares during the last quarter. Norges Bank bought a new stake in United Therapeutics in the 4th quarter worth approximately $293,418,000. Avoro Capital Advisors LLC boosted its stake in United Therapeutics by 17.3% in the fourth quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock worth $1,269,803,000 after buying an additional 383,838 shares in the last quarter. Finally, Janus Henderson Group PLC boosted its stake in United Therapeutics by 75.1% in the fourth quarter. Janus Henderson Group PLC now owns 796,101 shares of the biotechnology company’s stock worth $387,801,000 after buying an additional 341,383 shares in the last quarter. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

United Therapeutics Stock Performance

Shares of UTHR stock opened at $513.12 on Friday. United Therapeutics Corporation has a fifty-two week low of $302.19 and a fifty-two week high of $609.35. The firm has a market cap of $22.01 billion, a P/E ratio of 18.36, a P/E/G ratio of 1.74 and a beta of 0.59. The business’s 50 day moving average price is $533.08 and its 200-day moving average price is $537.36.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, topping analysts’ consensus estimates of $6.86 by $0.41. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The company had revenue of $783.30 million during the quarter, compared to analyst estimates of $804.65 million. During the same quarter last year, the firm posted $6.41 earnings per share. The firm’s revenue was down 1.9% on a year-over-year basis. As a group, equities analysts predict that United Therapeutics Corporation will post 26.33 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts have commented on the stock. Bank of America reduced their price target on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a research report on Friday, July 10th. JPMorgan Chase & Co. boosted their price objective on shares of United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a report on Thursday, July 23rd. Royal Bank Of Canada cut their price objective on shares of United Therapeutics from $704.00 to $677.00 and set an “outperform” rating for the company in a research note on Thursday, August 6th. Weiss Ratings raised shares of United Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a report on Thursday, August 13th. Finally, Wells Fargo & Company upgraded shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and lifted their target price for the stock from $575.00 to $735.00 in a research report on Thursday, May 7th. Eleven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $646.00.

Insiders Place Their Bets

In other news, CFO James Edgemond sold 10,000 shares of United Therapeutics stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $546.28, for a total transaction of $5,462,800.00. Following the sale, the chief financial officer owned 18,876 shares of the company’s stock, valued at approximately $10,311,581.28. The trade was a 34.63% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Martine A. Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $547.62, for a total transaction of $5,202,390.00. Following the sale, the chief executive officer directly owned 40,513 shares in the company, valued at $22,185,729.06. The trade was a 19.00% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 442,575 shares of company stock worth $239,326,330. Insiders own 8.60% of the company’s stock.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.